AI-Assisted Review for Acute Promyelocytic Leukemia

(LEAP Trial)

The trial aims to determine if artificial intelligence (AI) can assist doctors in diagnosing acute promyelocytic leukemia (APL), a rare blood cancer, more quickly and accurately. Doctors will review bone marrow samples in three ways: independently, with AI as a double-check, and with AI as the initial reviewer. The trial compares the impact of these methods on accuracy, speed, and confidence. This trial suits board-certified or eligible pathologists and hematologists who regularly diagnose blood disorders and are open to incorporating AI into their evaluations. As an unphased trial, it offers a unique opportunity to contribute to innovative research that could transform diagnostic practices.

The trial information does not specify whether you need to stop taking your current medications.

Research has shown that AI can help doctors diagnose acute promyelocytic leukemia (APL), a rare type of blood cancer, more quickly and accurately. AI could thus serve as a valuable tool in identifying this cancer.

Researchers are excited about the AI-assisted review for acute promyelocytic leukemia (APL) because it offers a novel approach to diagnosing this condition. Unlike traditional methods that rely solely on pathologists’ expertise, this AI system acts as both a double-check and a first look, potentially increasing accuracy and speed. By integrating AI, the process could become more efficient, allowing for quicker and possibly more precise diagnoses, which is especially crucial in critical conditions like APL. This technology could transform how pathologists work, ensuring they have cutting-edge tools to support their decision-making.

Research has shown that AI can be a helpful tool in diagnosing acute promyelocytic leukemia (APL), a rare type of blood cancer. In this trial, participants will undergo two different review processes: one with AI assistance first, followed by an unaided review, and another with the unaided review first, followed by AI assistance. Studies have found that AI systems like MC-100i effectively spot abnormal promyelocytes, a type of white blood cell, in blood samples. This capability helps doctors make faster and more accurate diagnoses. With AI's help, screening and identifying APL can occur more quickly, which is crucial for timely treatment. Overall, AI support in diagnosis can improve accuracy and boost confidence in medical evaluations.¹³⁴⁶⁷